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Abstract 
Purpose  
In oropharyngeal cancer adaptive radiation therapy (ART), this study aimed to quantify the dosimetric 
benefit of numerous replanning strategies, defined by various numbers and timings of replannings, with 
regard to parotid gland (PG) sparing.  
Material and methods 
Thirteen oropharyngeal cancer patients had one planning and then six weekly CT scans during the seven 
weeks of IMRT. Weekly doses were recalculated without replanning or with replanning to spare the PG. 
Sixty-three ART scenarios were simulated by considering all the combinations of numbers and timings of 
replanning. The PG cumulated doses corresponding to “standard” IMRT and ART scenarios were 
estimated and compared, either by calculating the average of weekly doses or using deformable image 
registration (DIR).  
Results 
Considering average weekly doses, the mean PG overdose using standard IMRT, compared to the planned 
dose, was 4.1 Gy. The mean dosimetric benefit of 6 replannings was 3.3 Gy. Replanning at weeks 1, 1-5, 
1-2-5, 1-2-4-5 and 1-2-4-5-6 produced the lowest PG mean doses, 94% of the maximum benefit being 
obtained with 3 replannings.	  The percentage of patients who had a benefit superior to 5 Gy for the 
contralateral PG was 31% for the three-replannings strategy. The same conclusions were found using DIR. 
Conclusion 
Early replannings proved the most beneficial for PG sparing, three replannings (weeks 1-2-5), 
representing an attractive combination for ART in oropharyngeal cancer. 
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1. Introduction 
 
Intensity-modulated radiation therapy (IMRT) has demonstrated its efficiency in head and neck cancer 
(HNC) by delivering highly-conformal doses to the tumor whilst sparing the organs at risk (OARs) [1-3], 
particularly the parotid glands (PGs). Large anatomical variations can, however, occur during the 
treatment, such as weight loss [4,5], primary tumor shrinking [4], parotid gland (PG) volume reduction 
[6], and neck diameter reduction [7-9]. These modifications may generate differences between the planned 
and actual delivered doses, inducing the risk of PG radiation overdose [10,11] that can potentially increase 
the risk of xerostomia [12]. 
Adaptive radiotherapy (ART), based on replanning(s) during the treatment, has proven able to decrease 
the PG mean dose during HNC IMRT [5], yet the optimal number and timing of these replannings are, to 
date, unclear. Different ART scenarios have been investigated and compared to a classical non-ART 
scenario with varying numbers and timings tested: one replanning performed either mid treatment [13], at 
week 2 [14] or at a patient-specific time based on weight loss or tumor shrinkage [10], two replannings at 
weeks 2 and 4 [13,15], three replannings at the 9th, 19th, and 29th fractions [16], and, the most extensive 
ART strategy, six weekly replannings [8,13]. All these studies show that ART results in a decrease of the 
PG mean dose. However, since the procedure of replanning is time consuming [17-19], the most optimal 
replanning strategy, i.e. the optimal number and timing of replanning, still requires thorough assessment.  
This study, focused on IMRT for oropharyngeal cancer, aimed to determine the best ART scenario, 
namely to assess the optimal number and timing of replanning for PG sparing. 
 
2. Materials and methods 
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2.1 Patients and tumors 
The study enrolled 13 patients with a mean age of 64 years (range: 50-76 years). All tumors were locally 
advanced oropharyngeal carcinomas (Stage III or IV, AJCC 7th ed). The PG mean volume was 25.9cc 
(range: 16.6-52.2 cc). Three ipsilateral PGs were completely included within the planning target volume 
(PTV), thus excluded from the study, resulting in a total of 23 PGs analyzed (13 contralateral and 10 
ipsilateral PGs). Table 1 shows the patient and tumor characteristics.  
 
2.2 Treatment and planning  
All patients underwent IMRT, receiving a total dose of 70 Gy (2 Gy/fraction, 35 fractions), with a 
simultaneous integrated boost technique [17] and concomitant chemotherapy. Planning computed 
tomography (CT0) was acquired with intravenous contrast agents using 2mm slice thickness, from the 
vertex to the carina. A thermoplastic head and shoulder mask with five fixation points was used. Positron 
emission tomography (PET) and magnetic resonance imaging (MRI) co-registration was used for tumor 
delineation. The gross tumor volume (GTV) corresponded to the primary tumor along with involved 
lymph nodes. Three target volumes were generated for each patient. A clinical target volume receiving 70 
Gy (CTV70) was equal to the GTV plus a 5mm 3D margin, which was adjusted to exclude any air cavities 
and bone mass showing no evidence of tumor invasion. CTV63 corresponded to the area at high-risk of 
microscopic spread, while CTV56 corresponded to the low-risk subclinical area. GTV, CTV63, CTV56, and 
all organs at risk were manually delineated on each CT slice by a single radiation oncologist. The PTVs 
were generated by adding a 5mm 3D margin around the CTVs. PTV expansion was limited to 3mm from 
the skin surface in order to avoid part of the build-up region and limit skin toxicity [20]. All IMRT plans 
were generated using Pinnacle V9.2. Seven coplanar 6-MV photon beams were employed with a step-and-
shoot IMRT technique. The prescribed doses were 70 Gy to the PTV70, 63 Gy to PTV63, and 56 Gy to 
PTV56. The collapsed cone convolution/superposition algorithm was used for dose calculation. The 
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maximum dose (D2%) within the PTV was 110% of the prescribed dose. The minimum PTV volume 
covered by the 95% isodose was 95%. Dose constraints were set according to the RTOG 
recommendations [21] as follows: spinal cord: maximum dose < 45 Gy, brainstem: maximum dose < 54 
Gy, optic nerves: maximum dose < 54 Gy, contralateral parotid: mean dose < 30Gy, median dose < 26 Gy, 
ipsilateral parotid: mean dose as low as possible, oral cavity: mean dose < 30 Gy, V30 < 65% and V35 < 
35% and lips: maximum dose < 30 Gy and mean dose < 20 Gy. PG sparing was not allowed if it was in 
detriment of PTV coverage and/or of other important OARs sparing. The treatment plans were performed 
by a single physicist. Initial planning characteristics are shown in Table 1. 
The time between CT0 acquisition and the start of the treatment was on average (range) 16 days (5-39 
days). The patients were treated as planned on the CT0 and no changes were applied to the parameters of 
the initial planning during the treatment (the following ART scenarios were generated for the dosimetric 
study only). During the treatment course, weekly in-room stereoscopic imaging was used to correct any 
set-up errors >5mm. All patients signed informed consent forms. The study was approved by the 
institutional review board (ARTIX study NCT01874587). 
 
2.3 Weekly dose estimations without replanning (non-ART scenario) 
During treatment, each patient underwent six weekly CTs (CT1 to CT6) (Figure 1) according to the same 
parameters as CT0, except for the intravenous contrast agents (not systematically used, particularly in case 
of cisplatin based chemotherapy). For each patient, the anatomical structures were manually delineated on 
each weekly CT by the same radiation oncologist without any propagation tool. For CTV70, the initial 
delineation at CT0 was maintained on each weekly CT with an adjustment to exclude any air cavities and 
bone mass showing no evidence of initial tumor invasion. When complete response was achieved, the 
initial macroscopically-involved areas were still included in the CTV70. The weekly doses (Figure 1, Step 
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1A) were then estimated by calculating the dose distribution on the weekly CTs (CT1 to CT6), using the 
same treatment parameters and isocenter as those in CT0 and a bone-based rigid registration to simulate 
patient setup. 
 
2.4 Replanning and ART scenarios  
A new IMRT plan was generated on each weekly CT, from week 1 (CT1) to week 6 (CT6) by the same 
physicist than for the planning (Figure 1, Step 1C). The replanning procedure corresponded to a new 
planning based on the re-contoured structures, using the same objectives and dose constraints than the 
initial planning on CT0, and above all respecting the RTOG recommendations [21]. Parotid sparing was 
not allowed if it was in detriment of PTV coverage and/or of other important OARs.  
All possible ART scenarios were simulated by considering 1 to 6 replannings and all possible timings. For 
example, for two replannings, 15 scenarios were simulated, taking into consideration the fact that 
replannings could occur at weeks 1 and 2 or weeks 1 and 3, and so on up to weeks 5 and 6. Thus, by 
considering one to six replannings with all possible timings, a total number of 63 ART scenarios were 
simulated.  
For each patient, each ART scenario corresponded to a series of six dose distributions calculated on the 
six weekly CTs. For each weekly CT, the most recent plan in the considered scenario was selected, i.e. 
either the initial plan or last replanning, for dose calculation. For example, in the case of two replannings 
at weeks 2 and 4, the following combinations of CT and plans were considered: CT1 – initial plan; CT2 – 
replanning; CT3 – week 2 replanning; CT4 – replanning; CT5 – week 4 replanning; CT6 – week 4 
replanning.  
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2.5 Parotid gland delivered dose estimation 
The cumulated dose according to the different scenarios was estimated in each PG using two different 
methods, calculating the average PG mean dose and by deformable image registration (DIR). 
- The average PG mean dose was analyzed by calculating the sum of the PG mean doses computed on the 
weekly CTs and normalized according to the number of CTs. 
- The cumulated dose was also computed as the sum of the dose distributions at different fractions (weekly 
CTs) mapped on the planning CT by considering the anatomical transformation between the fraction 
anatomies and planning anatomy. The anatomical transformation was estimated by delineation-based DIR. 
For each PG, a signed distance map was first generated to represent the internal and external squared 
Euclidean distance between each voxel and the PG surface. Distance maps of each PG were then 
registered using the Demons registration algorithm [22,23]. The resulting deformation fields were used to 
map the weekly dose distributions from the weekly CT to the planning CT using tri-linear interpolation. 
These mapped weekly dose distributions could be then added in order to calculate the cumulated dose. 
The Sorensen-Dice (DSC), a similarity coefficient computed between two regions [24], was used to 
evaluate the performance of the PG DIR. The average DSC, computed between the delineation on CT0 
and the delineations on weekly CTs propagated thanks to registration, was 0.66 (range: 0.36-0.88) and 
0.92 (range: 0.83-0.95) after bone-based rigid registration and DIR respectively.  
In total, average PG mean doses and DIR-based cumulated doses were therefore estimated for both the 
non-ART scenario and all ART scenarios. Each ART scenario was then compared to the non-ART 
scenario in terms of PG mean cumulated dose. For each ART scenario, the percentages of patients who 
had a benefit, compared to the non-ART scenario, superior to 4 Gy for both PGs, for at least one PG, for 
only the ipsilateral (IL) PG and for only the contralateral (CL) PG were computed. 
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2.6 CTV  delivered dose estimation 
The average CTV70 D98% (minimal dose received by 95% of the CTV70) was analyzed by calculating the 
sum of the CTV70 D98% computed on the weekly CTs and normalized according to the number of CTs, 
without and with ART. The CTV70 D98% (minimal dose received by 98% of the CTV70) was also 
analyzed. 
 
2.7 Statistical analysis 
The Wilcoxon signed-rank test was first used to compare the OARs (other than the PGs) and the PTVs 
doses (using the RTOG indexes) of the initial planning with the fraction doses of the weekly replannings. 
The Wilcoxon test was also carried out to compare the PG and CTV70 D98% doses of each ART scenario 
with the doses of the non-ART scenario. Statistical analysis was carried out using the R language and 
environment for statistical computing. 
 
3. Results  
 
CTV70 and PG volume differences over the course of the treatment (between CT0 and CT6) are shown 
Table 1. PTVs and OARs dosimetric indexes (other than those of the PGs) did not significantly differ 
between the initial planning and the weekly replannings. 
 
The optimal number and timing of replannings to spare the PG are presented first by calculating the 
average PG mean dose and secondly using the DIR method to cumulate the PG dose. 
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3.1 Optimal number and timing of replannings considering the average PG mean doses 
Relatively to the planning, the total number of overdosed PGs was 16 (9 CL and 7 IL), with a mean 
(range) overdose of 4.1 Gy (0.5 - 11.5 Gy). Figure 2 (superior part) shows the differences between the 
average PG mean dose for the non-ART (or each ART scenarios) and the PG planned dose (considered as 
the reference). The mean (range) dose difference between the non-ART scenario and the planned dose was 
1.7 Gy (-6.8 – 11.5 Gy) (red line in Figure 2).  
Relatively to the non-ART scenario, the mean and maximum dosimetric benefits of one to six replannings 
(highest benefit for a given number of replannings) considering both PGs were 2.2 Gy and 10 Gy with one 
replanning (week 1), 2.9 Gy and 10.6 Gy with two replannings (weeks 1 and 5), 3.1 Gy and 11.0 Gy with 
three replannings (weeks 1, 2 and 5),  3.2 Gy and 10.8 Gy with four replannings (weeks 1, 2, 4 and 5), 3.3 
Gy and 10.8 Gy with five replannings (weeks 1, 2, 4, 5 and 6) and 3.3 Gy and 10.8 Gy with six 
replannings (weeks 1 to 6), respectively. The dosimetric benefit of each of these ART scenarios for the CL 
and IL PGs is detailed in Table 2. Considering the maximum benefit obtained by six replannings, 94% of 
this benefit was therefore obtained with only three replannings, conducted at weeks 1, 2 and 5.  
Figure 2 (inferior part) presents the percentages of patients with a benefit higher than 4 Gy for all the 
scenarios and for at least one PG (IL or CL), both PGs (IL and CL), the CL PG and the IL PG. Figure 3 
presents the percentage of patients with a PG benefit of more than 0 to 12 Gy for the three-replannings 
scenario (weeks 1-2-5). 
 
3.2 Optimal number and timing of replannings considering the DIR-based cumulated PG doses 
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Relatively to the planning, the total number of overdosed PGs was 15 (9 CL and 6 IL), with a mean 
overdose of 3.8 Gy (0.6 – 9.6 Gy). Figure 4 (superior part) (supplementary material) shows the differences 
between the cumulated dose (for the non-ART and each ART scenarios) and the planned dose for all the 
PGs. The mean (range) dose difference between the non-ART scenario and the planned dose was 1.2 Gy (-
8.1 – 9.6 Gy) (red line in Figure 4).   
Relatively to the non-ART scenario, the mean and maximum dosimetric benefits of one to six replannings 
(highest benefit for a given number of replannings) considering both PGs were 2.2 Gy and 10.4 Gy with 
one replanning (week 1), 3.0 Gy and 10.9 Gy with two replannings (weeks 1 and 5), 3.1 Gy and 11.8 Gy 
with three replannings (weeks 1, 2 and 5), 3.3 Gy and 11.3 Gy with four replannings (weeks 1, 2, 4 and 5), 
3.4 Gy and 11.3 Gy with five replannings (weeks 1, 2, 4, 5 and 6) and 3.3 Gy and 11.3 Gy with six 
replannings (weeks 1 to 6), respectively. 
The dosimetric benefit of each of these ART scenarios for the CL and IL PGs is detailed in Table 3 
(supplementary material). Relatively to the maximum benefit obtained by six replannings, 95% of this 
benefit was obtained with only three replannings, performed at weeks 1, 2 and 5.  
Figure 4 (inferior part) (supplementary material) presents the percentages of patients with a benefit higher 
than 4 Gy for all the scenarios and for at least one PG (IL or CL), both PGs (IL and CL), the CL PG and 
the IL PG. Figure 5 (supplementary material) presents the percentage of patients with a benefit from 0 to 
12 Gy for the three-replannings scenario (weeks 1-2-5). 
 
3.2 CTV doses without ART and with ART 
Comparing the non-ART fractions to the planning, the CTV70 was underdosed in 73% of the fractions. 
The mean and the maximum differences of the CTV70 D98% between the non-ART fractions and the 
planning were 1.6 Gy and 3.1 Gy, respectively. 
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Comparing the ART to the non-ART fractions, increasing the number of replannings improved the CTV70 
coverage, as assessed by the mean CTV70 D98% presented in Table 2. 
 
4. Discussion 
 
The goal of our study was to compare different scenarios of replannings with regards to PG sparing in 
oropharyngeal cancer while, for each fraction, keeping the same PTV coverage than at the planning. By 
testing all different combinations of one to six weekly replannings during the 7 weeks of treatment, 
producing a total of 63 scenarios, we found that the maximum PG sparing was obtained with six 
replannings, resulting in an average mean dose decrease of 1.6 Gy (6.4 Gy max.) compared to the planned 
dose, and of 3.3 Gy (10.8 Gy max.) compared to the average dose without ART. Considering this six 
replannings scenario, 54% and 23% of patients had a benefit superior to 4 Gy in at least one PG and in 
two PGs, respectively. Three replannings, performed at weeks 1-2-5, were found to decrease the PG mean 
dose by 3.1 Gy (11.0 Gy max.) compared to the non-ART scenario, corresponding to 54% and 15% of 
patients having a benefit superior to 4 Gy in at least one PG and in both PGs respectively. This scenario 
thus resulted to more than 90% of the benefit obtained with the maximalist six replannings approach. The 
ART dosimetric benefit was higher for the contralateral PGs than for the ipsilateral PGs. ART strategies 
were therefore compared by considering both the PG dose difference and the percentage of patients who 
had a clinically meaningful PG benefit (superior to 4 Gy). Due to uncertainties in the estimation of the 
cumulated dose received by the PGs during the whole treatment, two different methods were used, one 
calculating the average of the weekly mean doses and the other one based on DIR. Both methods led to 
the same conclusions for the identification of the best replanning strategies. It must also be pointed out 
that the CTV was slightly underdosed in the vast majority of fractions when using a standard IMRT 
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without ART. Indeed, increasing the number of replannings also increased the coverage of the target. This 
correction of the tumor underdosage by ART could have however limited the PG sparring. 
While different numbers of replannings aimed at sparing the PG have been investigated in the literature, 
the optimal timing of these replannings has not been thoroughly assessed [8,13,15,16,25-34]. The 
endpoint of these studies was the quantification of the dosimetric benefit of sparing the PG, while keeping 
or even increasing the minimum dose in the PTV, using different CT-based IMRT replanning scenarios. 
Only one tested the clinical impact of replanning [33]. The number of patients analyzed per study also 
widely varied from 10 to 86. The number of replannings varied from one to six. The mid-treatment period, 
typically the third or fourth week, was generally chosen to test one [13,26,29-32] or two replannings 
[15,25,27,28]. Weekly replannings were tested in three studies [8,13,34]. Dose comparison was performed 
either at the fraction [28,30-32,34] or through the estimation of the cumulated dose by deformable image 
registration [8,13,25,26], or even by summing the dose-volume histograms [29].  
Compared to the planned dose, the contra-/ipsi- lateral PG doses were found to be decreased by 0.6/1.2 Gy, 
and 0.8/4.1 Gy when one and two replannings were conducted, respectively [26]. Two replannings have 
also shown to decrease the PG median dose by 2.2-7.1% [15,27]. One mid-course replanning and six 
replannings resulted in decreasing the PG mean dose by 3 and 6%, respectively [13]. A weekly replanning 
schedule decreased the PG mean dose by 3.6 Gy [8] or by 3% per week [13]. Our results appear relatively 
similar to those in the literature for a given tested scenario. Nevertheless, one study found no benefit 
through performing four replannings [25]. In their results, the PG mean dose at planning, cumulated dose 
without replanning, and cumulated dose with replanning were 17.9 Gy, 18.7 Gy, and 18.7 Gy, respectively. 
The PG mean planned dose was thus lower in their study than in our work, probably due to the irradiated 
tumor site comprising only one oropharyngeal tumor. Such results suggest that the oropharyngeal site 
could benefit the most from an ART strategy. In total, the majority of the studies suggest that the more 
replannings are used, the more the PG can be spared, and especially so for oropharyngeal tumors. 
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However, despite large anatomical variations, Ho et al. did not find any dose difference for the OARs in a 
nasopharyngeal tumor cohort [35]. This series differs however from our work again by the primary tumor 
(nasopharyngeal versus oropharyngeal tumor), by the smallest planned dose (65 Gy versus 70 Gy) which 
may impact the position of the dose gradient relatively to the PGs, and by the use of neoadjuvant TPF 
chemotherapy in 30% of the patients which reduced the CTV before the radiotherapy. It must also be 
pointed out that, in our series, the proportion of “spontaneously” underdosed PGs (range 6.8 – 1.5 Gy) 
without any replanning (i.e. standard IMRT) was surprisingly 30%, which may be explained by the 
shrinkage of the PGs that could move them away from the high dose area.  
The clinical impact of replanning was evaluated in only one series involving 86 patients with 
nasopharyngeal cancer [33]. One or two replannings were performed at the third and fifth weeks, with no 
anatomical or dosimetric selection criteria. A comparison was performed with 43 patients who refused 
replanning. Replanning improved both the patients’ quality of life and localized disease control, yet had 
no impact on overall survival.  
Limiting the number of replannings is a crucial issue, given the burden each supplementary replanning 
entails. In previous studies, the mid-treatment period or 5th week (at the boost) was selected for one 
replanning [36,37]. In contrast, our results show that the beginning of the treatment (first two weeks) is the 
most crucial time for replanning. The CTV shrinkage is, in fact, particularly significant during this early 
period of radiotherapy [38], and PG overdose at the end of the treatment has been shown to be highly 
correlated with overdose on the first treatment day [39]. Moreover, the earlier the replanning is performed, 
the more it will impact on the treatment. The strong impact of the first week replanning suggests also 
reducing the delay between the initial planning and the beginning of treatment. While our study 
demonstrated that each supplementary replanning decreases the PG mean dose, three replannings at weeks 
1-2-5 do, however, appear to offer a good compromise, achieving 94% of the maximum weekly 
replanning benefit. From a previous maximalist replanning strategy study, we found that the benefit of 5 
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Gy could reduce the xerostomia risk of nearly 10% [8]. Our study motivates the use of a three-replannings 
strategy to reduce the doses at the CL PG of 5 Gy for 31% of our cohort, leading to a non-negligible 
reduction of the xerostomia risk. However, the mechanisms leading to xerostomia and its resolution are 
complex and remain to elucidate. A recent study has shown that an early PG shrinkage is predictive of 
xerostomia resolution [40], still showing the importance of the first weeks of treatment. Considering the 
parotid glands as a unified organ also have some limitations since some specific sub-regions of parotids, 
where salivary stem cells are concentrated, may be preferentially related to xerostomia [41]. 
This study also shows that considering the individual benefit of the replannings separately is not sufficient 
to assess their combinations. Indeed, the synergy between replannings at different times should also be 
exploited to obtain the best PG sparing. The efficiency of a given replanning is actually related to the 
combination of two factors: (i) the anatomical modifications it will enable to compensate with respect to 
the previous (re-)plan and (ii) the duration this new plan will be used, i.e. corresponding to the number of 
fractions the new plan will be applied until the end of the treatment or a new replanning.  
Another way to limit the number of replannings could be a more patient-specific approach based on 
anatomical or dosimetric predictors of PG overdose [42]. Ideally, these criteria should be defined on both 
pre-treatment planning CT and per-treatment cone-beam CT (CBCT). Due to the poor image quality, 
limited field of view and complexity of the dose calculation, such CBCT based approach has however not 
been yet solved. We therefore opted for weekly CT scans for dose calculation, also assuming that the 
anatomy at the fraction was representative of the anatomy of the whole week of treatment. We also 
simulated the patient setup by a bone-based rigid registration, neglecting therefore the setup error. 
The main limitation of this study is the small number of patients. The results may also depend however of 
the full IMRT procedure (delineation, IMRT technique, dose constrains and objectives, timing of the 
CTs…). The conclusion of our study should be therefore considered carefully, with a need for an external 
validation cohort to confirm the results. Our monocentric study appears nevertheless homogeneous since 
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comprising oropharyngeal tumors only, a single radiation oncologist for all the delineations and a single 
physicist for the (re)plannings. Moreover, the PG cumulated doses have been estimated by using both a 
mean dose approach and an elastic registration method, leading to concordant statistically significant 
conclusions. Finally, if the cumulated doses to the target and the OARs (other than the PGs) were not 
estimated, the PTV coverage and OARs sparing were not significantly degraded between the initial 
plannings and the replannings. Clinical finding should finally confirm the pertinence of the ART strategy.     
 
5. Conclusion 
 
Three replannings conducted at weeks 1, 2 and 5 appear to offer a pragmatic and attractive ART strategy 
enabling a decrease of the PG dose by 3.1 Gy in locally-advanced oropharyngeal carcinoma, while also 
increasing slightly the target coverage. Clinical trials are, however, needed to demonstrate the benefit of 
this approach in terms of decreasing the risk of xerostomia while keeping the same local control. 
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Table 1: Patient, tumor and initial planning (CT0) characteristics and volume differences over the 
course of the treatment (between CT0 and CT6) 
ID Gender Age TNM 
Volume at CT0 (cc) 
Dmean at CT0 
(Gy) 
Volume variation between CT0 
and CT6 (in %) 
CTV70 ILP CLP ILP CLP CTV70 ILP CLP 
1 M 76 T3N1 45.2 52.1 48.6 30.2 31.1 -53.1 -10.0 -55.0 
2 F 63 T2Nx 26.3 31.2 27.6 31.4 25.0 6.7 -26.3 -21.6 
3 M 74 T3N2c 181.6 24.9 20.7 37.0 31.2 -10.2 -34.0 -3.0 
4 F 66 T2N2c 107.2 27.8 23.5 32.0 27.9 8.6 -30.1 -24.9 
5 M 57 T3N0 62.5 20.7 18.0 28.1 27.8 -55.4 -57.6 -15.4 
6 M 67 T3N2c 156.2 24.5 22.7 27.6 29.4 -40.1 -12.7 -39.8 
7 M 52 T4N2 174.0 N/A 21.6 N/A 28.7 -13.2 N/A -43.1 
8 M 67 T4N1 139.4 22.0 19.3 30.7 29.2 -8.5 -49.8 -57.3 
9 F 65 T3N3 237.6 24.0 20.3 42.4 31.1 -56.1 -24.9 -30.8 
10 F 65 T4N3 257.9 N/A 24.6 N/A 35.3 12.6 N/A -18.6 
11 M 50 T4N2c 434.6 N/A 17.8 N/A 36.3 -62.1 N/A -54.2 
12 M 53 T3N0 14.4 16.6 23.3 41.4 24.3 -14.1 -44.8 -5.2 
13 M 73 T3N2c 147.0 29.5 29.3 54.6 32.2 -32.7 -54.9 5.2 
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M: male; F: female; CT0: initial planning; CTV70: clinical target volume receiving 70 Gy; PGs: parotid 
glands; ILP: ipsilateral PGs; CLP: contralateral PGs; Dmean: mean dose at initial planning; N/A: not 
applicable (PGs included in the CTV); Volume variation: volume difference between the planning CT and 
the last CT (in percentage)  
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Table 2: Best ART scenario of replanning(s) to spare the PG considering the average PG dose to 
cumulate the dose in the PGs 
Number of 
replannings 
Best week(s) for 
replannings 
Average CL PG 
dose (Gy) 
mean (min – max) 
Average IL PG 
dose (Gy) 
mean (min – max) 
Average D98% of 
CTV70 (Gy) 
mean (min – max) 
0 N/A 31.7 (18.1 – 44.3) 37.4 (29.4 – 57.2) 67,8 (66,1 – 69,5) 
1 w1 29.6 (18.2 – 39.3) * 35.2 (24.4 – 50.6) * 68,1 (66,3 – 69,7) 
2 w1, w5 28.6 (18.2 – 35.8) * 34.8 (24.0 – 50.7) * 68,4 (67,3 – 69,4) * 
3 w1, w2, w5 28.3 (18.3 – 38.8) * 34.8 (24.2 – 51.4) * 68,4 (67,3 – 69,5) * 
4 w1, w2, w4, w5 28.1 (18.0 – 37.1) * 34.7 (24.3 – 51.2) * 68,7 (67,5 – 69,7) * 
5 w1, w2, w4, w5, w6 28.0 (18.0 – 37.1) * 34.6 (25.3 – 51.3) * 68,7 (67,6 – 69,7) * 
6 w1, w2, w3, w4, w5, w6 28.0 (17.9 – 36.4) * 34.7 (26.1 – 51.2) * 68,9 (67,7 – 70,0) * 
 
W: week; N/A: not applicable; PG: parotid gland, CL: contralateral, IL: ipsilateral  
The given PG doses correspond to the PG mean dose (Dmean). For each patient and each replanning 
scenario, the PG dose delivered during the whole treatment was estimated by calculating Dmean average.  
The CL and IL PG mean (range) planning Dmean were 30.0 Gy (24.3 – 36.4 Gy) and 35.8 Gy (27.7 – 54.6 
Gy) respectively (Table 1). The mean (range) planning CTV70 D98% was 69.1 Gy (68.2 – 70.0 Gy). 
Compared to the non-ART scenario (0 replanning), increasing the number of replannings significantly 
decreased the PG mean dose (* in the 2nd and 3rd column) and increased the CTV coverage (* in the 5th 
column)  (* Wilcoxon test with p < 0.05). 
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Table 3 (Supplementary material): Best ART scenario of replanning(s) to spare the PG, considering 
deformable image registration to cumulate the dose in the PGs  
Number of 
replannings 
Best week(s) for 
replannings 
DIR Cumulated CL PG dose 
(Gy) 
mean (min – max) 
DIR Cumulated IL PG dose 
(Gy) 
mean (min – max) 
0 N/A 31.6 (19.3 - 41.9) 36.6 (27.3 - 57.6) 
1 w1 29.5 (19.4 - 37.7)  34.3 (24.9 - 50.6) * 
2 w1, w5 28.3 (19.5 - 33.6) * 34.0 (24.6 - 50.8) * 
3 w1, w2, w5 28.0 (19.5 - 35.8) * 34.0 (25.3 - 51.5) * 
4 w1, w2, w4, w5 27.8 (19.2 - 33.7) * 34.0 (25.4 - 51.4) * 
5 w1, w2, w4, w5, w6 27.7 (19.2 - 33.7) * 33.8 (25.9 - 51.4) * 
6 w1, w2, w3, w4, w5, w6 27.7 (19.2 - 32.7) * 34.0 (25.9 - 51.3) * 
 
W: week; N/A: not applicable; PG: parotid gland, CL: contralateral, IL: ipsilateral  
The given PG doses correspond to the PG mean dose (Dmean). For each patient and each replanning 
scenario, the PG dose delivered during the whole treatment was estimated by deformable image 
registration.  
Compared to the non-ART scenario (0 replanning), increasing the number of replannings significantly 
decreased the PG mean dose (* in the 2nd and 3rd column). 
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Figure 1: Study workflow 
 
 
CT: computed tomography; W: week 
The weekly doses were recalculated without replanning (step 1A) or with replanning (step 1C). The 
cumulated doses without replanning (step 1B) and for each scenario of replanning (step 1D) were 
calculated by average mean dose and deformable image registration, and then the doses were compared 
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Figure 2: Benefit of replanning(s) to spare the PGs for each ART scenario, considering the average 
PG mean doses 
 
ART: adaptive radiation therapy; PG: parotid gland; CL: contralateral; IL: ipsilateral 
Each boxplot represents the difference between the cumulated dose and the planned dose for each of the 
63 ART scenarios and the 23 parotid glands (PG). Each scenario is identified by the week(s) of 
replanning(s), ordered by increasing number of replannings (CT1 to CT6). 
The limits of each box represent the 25th and 75th percentiles, the whisker represents the most extreme data 
points and the black line represents the median. The horizontal black line represents the reference of the 
dose differences, which is the planned dose on CT0. The red dotted line represents the median cumulated 
dose difference of the cohort (from the non-ART or “0 replanning” boxplot).  
The color points in the inferior part represent the percentage of patients who had, for each scenario, a 
benefit superior to 4 Gy compared to the delivered dose (non-ART) for both PGs in black, at least one PG 
in green, only the IL PGs in blue and only the CL PGs in red compared to the cumulated dose.  
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Figure 3: Percentage of patients with a PG benefit of more than a given threshold dose for the three-
replannings scenario (weeks 1-2-5), considering the average PG mean doses to cumulate the dose in 
the PGs 
 
Each curve represents the percentage of patients with a PG benefit (mean dose) of more than a given 
threshold dose for both parotid glands (in red), at least one (in black), the contralateral one (in blue) and 
the ipsilateral one (in green). 
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Figure 4 (Supplementary material): Benefit of replanning(s) to spare the PGs for each ART 
scenario, considering DIR-based cumulated PG doses  
 
ART: adaptive radiation therapy; PG: parotid gland; CL: contralateral; IL: ipsilateral 
Each boxplot represents the difference between the cumulated dose and the planned dose for each of the 
63 ART scenarios and the 23 parotid glands (PG). Each scenario is identified by the week(s) of 
replanning(s), ordered by increasing number of replannings (CT1 to CT6). 
The limits of each box represent the 25th and 75th percentiles, the whisker represents the most extreme data 
points and the black line represents the median. The horizontal black line represents the reference of the 
dose differences, which is the planned dose on CT0. The red dotted line represents the median cumulated 
dose difference of the cohort (from the non-ART or “0 replanning” boxplot).  
The color points in the inferior part represent the percentage of patients who had, for each scenario, a 
benefit superior to 4 Gy compared to the delivered dose (non-ART) for both PGs in black, at least one PG 
in green, only the IL PGs in blue and only the CL PGs in red compared to the cumulated dose.  
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Figure 5 (Supplementary material): Percentage of patients with a PG benefit of more than a given 
threshold dose for the three-replannings scenario (weeks 1-2-5), considering DIR-based cumulated 
PG doses  
 
Each curve represents the percentage of patients with a PG benefit (mean dose) of more than a given 
threshold dose for both parotid glands (in red), at least one (in black), the contralateral one (in blue) and 
the ipsilateral one (in green). 
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